📰 Global Head Cell News

Global Head Cell News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Global Head Cell. Real-time updates on events, politics, business and more.

Business.Scoop » DIA And CoRE Gathering Key Healthcare Experts In Neutral Forum To Discuss Regulatory News And Drug Development

June 15, 2022

Business Scoop provides news and views on Business and Markets from New Zealand

Daniela Caiazza Novotech Serena Chan Ralf Altenburger Daniela Caiazza Ali Al Shin Ichi Okudaira Jesusa Joyce

Source: scoop.co.nz

Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma

June 2, 2021

/PRNewswire/ -- Novartis today announced robust data from the primary analysis of the pivotal Phase II ELARA trial of Kymriah® (tisagenlecleucel) in patients...

United States Julie Masow Jamie Bennett Stephenj Schuster Sloan Simpson Stefan Hendriks

Source: prnewswire.com

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma

June 2, 2021

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma

United States Isabella Zinck Thomas Hungerbuehler Stephenj Schuster Samir Shah Julie Masow

Source: investegate.co.uk

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Global Head Cell News Today

Business.Scoop &#xBB; DIA And CoRE Gathering Key Healthcare Experts In Neutral Forum To Discuss Regulatory News And Drug Development

Novartis Kymriah&#xAE; pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Kymriah&#xAE; pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma

Explore More Categories

Business.Scoop » DIA And CoRE Gathering Key Healthcare Experts In Neutral Forum To Discuss Regulatory News And Drug Development

Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma